AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time ...

AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Medicine Agency (EMA) has approved the extension of the shelf-life of its veterinary medicine MASIVET® from 36 months to ...

AB Science SA (Euronext - FR0010557264 - AB) today announces that The Life Sciences Magazine, a leading publication in the fields of healthcare and medical advancements, has featured an exclusive ...

After years of disappointment, things might seem to be looking up for the amyotrophic lateral sclerosis patient community. Two weeks ago they got a new drug approved by the FDA, and now French biotech ...

While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...

AB Science SA (Euronext - FR0010557264 - AB) today provides an update on its masitinib platform. The webcast presentation is available on the company's website, in ...

Update on the AB8939 microtubule program and in particular on the ability of AB8939 to generate a response on MECOM rearrangement AB Science provided an update on the microtubule program AB8939.

AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Paris, October 10, 2025, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces its ...

Ab Science ( (ABSCF)) has released its Q2 earnings. Here is a breakdown of the information Ab Science presented to its investors. Take advantage of TipRanks Premium at 50% off! Unlock powerful ...

A six-pack is at the top of many a fitness wishlist, but the benefits of performing the best ab exercises go far beyond aesthetics. Abs are part of the core muscles in your body, which are responsible ...

AB Science announced in March 2023 a case report from the initial stage of its Phase I/II study (AB18001) evaluating AB8939, a microtubule destabilizer, in patients with refractory and relapsed acute ...